An interventional study of Indometacin suppository and Lactated ringers solution in Pancreatitis, Chronic, Pancreatitis, Acute and Pancreatic Duct Stones, sponsored by Changhai Hospital. Recruiting at 10 sites in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-04-13.
Sponsored by Changhai Hospital · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies in Pancreatitis, Chronic by Changhai Hospital — 13 open to participants now, 18 under way, none of them phase 3. Pancreatitis, Chronic · Changhai Hospital.
Among the 41 studies in Pancreatitis, Chronic by Changhai Hospital, this one is the 2nd largest by planned enrollment of the 13 interventional ones that give a count, is one of 9 that started in 2025, is one of 11 with no phase, reaches primary completion later than 11 of the 17 other live ones, and was the 38th registered.
266 studies on the registry are indexed under Pancreatitis, Chronic; 76 are open to participants now.
Browse Pancreatitis, Chronic studies →13 of the 41 studies in Pancreatitis, Chronic by Changhai Hospital are open now, in 1 country. Recruiting first, the newest first:
Changhai Hospital · Sites in China
Ages 18–80
Changhai Hospital · Sites in China
Ages 18–85
Changhai Hospital · Sites in China
Ages 18+
Changhai Hospital · Sites in China
Ages 18–65
Changhai Hospital · Sites in China
By country, each count listing its studies:
Of the 49 Pancreatitis, Chronic studies recruiting now, 31 (63%) set no upper age limit and 12 (24%) stop at 75 or younger; 8 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 9 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,250 is above the median of 47 across 142 interventional studies indexed under Pancreatitis, Chronic.
Median enrollment 134 across the 13 interventional studies, 657 across the 28 observational. Of the 15 that completed or were terminated, 1 (7%) have results posted.
This tab as a report to print or save as PDF → With an account.
Changhai Hospital is the lead sponsor of 355 studies on the registry; 136 are open to participants now.
1 of the studies in Pancreatitis, Chronic by Changhai Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03324698Changhai HospitalThe Natural History of Chronic Pancreatitis | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 41 studies in Pancreatitis, Chronic by Changhai Hospital, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study aims to determine whether combining aggressive intravenous hydration with indometacin is more effective at preventing pancreatitis after a Extracorporeal Shock Wave Lithotripsy (ESWL) than using indometacin alone.
The study will involve patients who are scheduled to undergo ESWL for pancreatic stones. Participants will be randomly assigned to one of two groups: one will receive both the intravenous hydration and the rectal indometacin, while the other will receive only the rectal indometacin.
The trial will be conducted at multiple centers, ensuring a broad and diverse patient population.
The primary outcome of the study will be the incidence of pancreatitis after the ESWL procedure.
This study is important because it could lead to a better understanding of how to prevent pancreatitis after ESWL, potentially improving patient outcomes and reducing the risk of serious complications.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this arm will receive a rectal administration of 100mg indometacin 30 minutes prior to ESWL. This group will not undergo aggressive hydration and will instead receive restricted hydration measures.
Drug: Indometacin suppository · Drug: Normal Saline
Participants in this arm will also receive a rectal administration of 100mg indometacin 30 minutes before ESWL. In addition, they will undergo aggressive intravenous hydration using lactated Ringer's solution.
Drug: Indometacin suppository · Drug: Lactated ringers solution
Administration of a 100mg indometacin suppository rectally 30 minutes prior to ESWL
Intravenous 20 mL/kg Ringer's lactate solution within 60 min from the start of ESWL, directly followed by 3 mL/kg per h for 8 h.
Intravenous fluid infusion with normal saline (maximum of 1.5mL/kg per h or 3L per 24h)
Incidence of post-ESWL pancreatitis
Post-ESWL pancreatitis is defined according to the 2012 Atlanta criteria. A diagnosis of post-ESWL pancreatitis is made if two of three of the following criteria are met: pain consistent with pancreatitis; amylase or lipase of at least three times the upper normal limit within 24 h of the procedure; or characteristic findings on imaging.
Time frame: 24 hours
Severity of pancreatitis
Stratified as mild, moderate, or severe, mainly on the basis of length of hospitalization and need for invasive treatment.
Time frame: 1 month
Incidence of other post-ESWL complications
Including bleeding, infection, steinstrasse, and perforation.
Time frame: 24 hours
Incidence of fluid overload
Including pulmonary or peripheral edema and congestive heart failure.
Time frame: 24 hours
Transient adverse events related to ESWL
Transient adverse events were defined as transient injuries caused by shock waves that required no medical intervention and did not prolong hospitalisation, including asymptomatic hyperamylasaemia, haematuria, and acute gastrointestinal mucosal injury (eg, haematemesis, melena, or haem atochezia) caused by ESWL. Asymptomatic hyper amylasaemia was defined as an increase in serum amylase compared with pre ESWL levels and beyond the upper limit of the normal range but showing no related symptoms.
Time frame: 24 hours
Length of hospitalisation
Time frame: 1 month
Plan to share: Undecided
No publications or documents are linked to this record.
Started Oct 2025 (actual). Primary completion is estimated for Dec 2027, 25 months after the start.
Of 46 non-industry interventional studies with no phase under Pancreatitis, Chronic, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 64. This study's planned 25 months is below that.
Counting every sponsor, half of 49 studies reached it within 32 months; a quarter within 18 and three quarters within 64.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ringer's Lactate